Industry – Page 17 – Swanson Reed | Specialist R&D Tax Advisors

B9Creations: Revolutionizing Osteoarthritis Research with Cutting-Edge Technology

For decades, researchers have struggled to find a cure for osteoarthritis, a disease that affects millions of people worldwide. However, Rapid City-based additive manufacturing solutions provider B9Creations is now partnering with a South Dakota Mines research team to find a solution to this debilitating condition.

Together, they are developing a “joint-on-a-chip” device – an evolution of “lab-on-a-chip” – that will allow researchers to study the complex interactions between cells in human joints. Using B9Creations’ 3D printing technology, the Mines research team has patented a breakthrough technology called CellWell, which, when combined with 3D-printed housing, enables the study of cartilage cells in a way that mimics their natural state. This unique combination of tools is offering new insights into the causes of osteoarthritis, which were impossible to gain before.

Scott Wood, Ph.D., an assistant professor in the NanoScience and Biomedical Engineering Department at Mines, and his students led the research and development of this groundbreaking technology, which they now utilize in their startup, CellField Technologies. According to Wood, osteoarthritis is not just a “wear and tear” disease, but rather an imbalance of the behavior of the cells in the joint.

CellWell technology uses a combination of nanotechnology, micropatterning, and mechanically-tunable thin-film composite materials to create an environment that allows cartilage cells to maintain their physiological nature without restricting their ability to be studied. Compared to competing technologies, CellWell can maintain the physiological cell shape and biomarker profile of chondrocytes for at least 28 days, four times as long as others.

The project has received funding from the National Science Foundation, the Governor’s Office of Economic Development, and DRACO, a South Dakota nonprofit organization that advises startup companies and entrepreneurs. The team’s technology is aimed at small to mid-sized pharmaceutical companies, who are most focused on finding cures for osteoarthritis.

Wood’s work has been recognized with a National Science Foundation CAREER Award, which is the most prestigious award for early-career faculty. He is one of four faculty at Mines to receive this award since 2015 and the second from the NanoScience and Biomedical Engineering Department. Wood was also a finalist in the South Dakota Governor’s Giant Vision Competition.

With the development of CellWell technology, B9Creations and the Mines research team are paving the way for a cure for osteoarthritis. By studying cartilage cells in a way that mimics their natural state, researchers will be able to gain new insights into the behavior of the cells in the joint, which will be invaluable in developing new treatments for this debilitating disease.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing Digestive Health: Oshi Health Takes Up $30M In Series B Funding

Digestive disorders affect 1 in 4 Americans and have a high economic burden, driving $135 billion in annual costs. Traditional GI care often leaves patients unsupported between visits, leading to prolonged suffering, high avoidable costs, and long wait times for appointments. But what if there was a way to address these issues and provide comprehensive care for digestive disorders? This is exactly what Oshi Health is aiming for.

Oshi Health, a virtual gastrointestinal care clinic, has recently raised $30 million in series B funding to scale up its technology and meet the growing demand from patients, employers, health plans, and provider groups. This brings their total funding to $59.5 million, and they have partnerships with health platform Solera Health and virtual care company Firefly Health.

Oshi Health is addressing issues including Crohn’s disease and ulcerative colitis, using a comprehensive approach with gastroenterologists, dietitians, behavioral health support, and care coordinators. Their virtual multidisciplinary care resulted in significantly higher levels of patient engagement, satisfaction, and symptom control, as per a prospective study sponsored by Oshi Health.

Moreover, the recent clinical study results are driving accelerated contracting with payers and employers to reimburse access to Oshi Health as a covered benefit. Oshi Health’s services also drove all-cause medical cost savings of $10,292 per patient in just six months, the study found.

The company connects users with an integrated care team consisting of GI specialists including board-certified gastroenterologists, registered dietitians, GI-specialized mental health clinicians, and nurse practitioners. Oshi Health’s approach is to get to the root causes of chronic digestive symptoms and help members understand their own dietary and psychological triggers through iterative treatment and response.

The company’s platform is currently available to over 20 million people as a preferred in-network virtual gastroenterology clinic for national and regional insurers as well as their employer customers. Oshi Health also partners with community GI practices in a collaborative hybrid model to extend access to care, including reimbursed access to dietary and behavioral therapies.

The new funding will accelerate the next phase of Oshi Health’s growth, to scale its clinical team nationwide and forge relationships with health plans, employers, channel partners, and provider groups. “Our investors are collectively funding the change-makers in the most crucial categories of healthcare,” said Sam Holliday, Oshi Health CEO. “They see the transformation opportunity and urgency in digestive care as clearly as we do, and we’re proud to have them back our mission to free millions of Americans from their struggle with digestive symptoms and conditions.”

Oshi Health’s success is part of a growing list of virtual-first companies focused on gastrointestinal care, and the sector is attracting more investment dollars. Ayble Health launched last year with $4.6 million in seed funding, and Salvo Health, a New York-based virtual health clinic focusing on specialty care for chronic gut conditions, nabbed $10 million in seed funding. Oshi Health’s unique care model, which provides comprehensive care and addresses chronic digestive symptoms, is revolutionizing digestive health.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Mobeus: Revolutionizing Telepresence and Self-Expression with Innovative Transparent Computing Technology

Missouri Patent of the Month - December 2021

Mobeus, a startup based in Sparta, New Jersey, is making waves in the tech world with its innovative product, Airglass. The product is a video and audio communications tool that enhances virtual meetings by using transparent computing. It is a user-centric computing scheme that separates hardware and software to convert desktop software into a transparent, glass-like layer, giving the user the impression of looking beyond the display screen. The company has submitted around 70 patents, with 12 already issued and being pursued internationally. The Airglass product serves as both a commercial product and a way to test the technology in the market.

Mobeus was founded when the COVID pandemic highlighted limitations in the existing telepresence systems. The founders began working towards something foundational that could be a product and a platform. The team figured out how to turn the whole front of the computer into an interactive 3D presentation and turn the entire display of the computer into immersive glass.

The company is using Airglass to take telepresence places it has never been before and believes that the product will revolutionize how people express their creativity. The user experience with Airglass isn’t as immersive as with virtual reality or augmented reality, but it meets consumers right where they are right now. The company does not think this technology will replace VR headsets; however, when using this technology, the screen becomes 3D instead of 2D, introducing a new way to operate the computer and a new way to communicate and collaborate.

Mobeus has 40 employees, with 10 of them living in New Jersey. The company’s funding came from some ultra-high net worth individuals and Accenture Ventures, according to Richie Etwaru, co-founder and chief creative officer at Mobeus. The company is now one of the most innovative startups in New Jersey, offering a great example of how a small startup with a big idea can disrupt an entire industry.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Laborie Medical Technologies takes the lead in diagnosing GERD with alpHaONE System

GERD, or gastroesophageal reflux disease, affects millions of people worldwide. Its diagnosis can be difficult, as current methods include invasive endoscopic exams and X-rays. But Laborie Medical Technologies is changing the game with their alpHaONE system—a wireless device that can be implanted in the esophagus and collect data for up to four days.

The alpHaONE system works by placing a small sensor capsule on the esophageal wall, a short distance from the stomach, and recording changes in pH levels over time. This data is then transmitted to a handheld device that logs the information and allows the user to document their meals, time spent lying down, and feelings of heartburn, coughs, or deep belches.

One of the standout features of the alpHaONE system is its ease of use. Patients can carry the handheld device with them wherever they go, making it easy to track their symptoms and lifestyle habits. Laborie also offers a virtual instruction program to help patients better understand how to use the device and interpret the data.

The New Hampshire-based company estimates that about 1 in 5 people in the U.S. may suffer from GERD. With the alpHaONE system, these patients can now receive a more accurate diagnosis and better manage their condition.

Laborie is a global medical technology company specializing in Gastroenterology, Urology & Urogynecology, and Obstetrics, Gynecology & Neonatal. Through the development and manufacture of high quality, high impact diagnostic and therapeutic products, Laborie consistently contributes to the improvement of patient outcomes.

The alpHaONE system is just one example of the many exciting developments happening in the world of medical research and development. As technology continues to advance, we can expect to see even more innovative solutions that will improve patient care and outcomes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Red Way: A New Hope for Lincoln’s Struggling Airport – Exploring the Prospects of a New Ultra-Low-Cost Carrier

Stratodynamics Shows Pomise in Unmanned Aerial Turbulence Detection

Lincoln, Nebraska, a city known for its history and recreational facilities, has become a battleground for a new startup called Red Way, which has stepped up to fill the void left by legacy carriers withdrawing from the city. Red Way is an ultra-low-cost carrier that is aiming to operate twice-weekly flights to major cities across the United States.

Red Way’s modus operandi is unique, as it functions as a “virtual airline” by handling sales and bookings via a Red Way-branded website, while Florida-based charter operator Global Crossing Airlines will supply and operate the aircraft. The airline has already received revenue guarantees in the form of COVID-19 relief funds from the city and county, totaling $3 million.

Red Way’s business model is centered around leisure markets, which can be tricky given the impact of the COVID-19 pandemic on the travel industry. However, Red Way CEO Nickolas Wangler is confident that the company will succeed. The airline plans to fly to destinations such as Atlanta, Austin, Dallas, Las Vegas, Minneapolis, Nashville, and Orlando, and it aims to respond directly to consumer demand, meaning it will cancel routes that don’t resonate with passengers. In addition, Red Way plans to add more flights to warmer destinations in the US during the winter months.

Although the concept of Red Way seems promising, industry experts and bloggers have expressed concerns about its long-term viability. Some analysts have criticized the airline’s limited flight schedule and its pricing structure, which requires passengers to pay extra for additional services such as carry-ons and checked bags. Moreover, recent Department of Transportation data reveals that few people have been flying the new routes added by Red Way.

Despite the challenges, the airline is optimistic about its future. The company has a strong community backing, and it is hoping to cater to a demand for low-cost leisure travel to destinations that are currently not served by other carriers. Red Way’s first flight from Lincoln Airport is scheduled to depart for Orlando on June 16.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Miromatrix Reports Promising Results and Advances in Bioengineering Fully Transplantable Organs

Miromatrix Medical Inc. has released a corporate update along with their 2022 financial report. The company’s primary objective for the year ahead is the initiation of a Phase 1 clinical trial for miroliverELAP. This new bioengineered organ technology, which is focused on providing patients with acute liver failure access to fully transplantable organs, is a significant milestone that, once achieved, will provide vital validation. The company is also concentrating the majority of its resources on miroliverELAP™ to achieve the clearance for IND (investigational new drug) to enable testing by the end of 2023.

Miromatrix has a collaborative research agreement with Baxter International Inc. relating to miroliverELAP™, which it announced on February 1, 2023. miroliverELAP™ is a liver therapy which combines Miromatrix’ single-use bioengineered liver with Baxter’s PrisMax system. The Phase I clinical trial will look to treat patients suffering from acute liver failure. The company has also revealed that presentations have been selected for the American Transplant Congress in June 2023, which will relate to mirokidney and miroliverELAP™.

Miromatrix Medical is making significant progress in bioengineering fully transplantable human organs to address the shortage of available organs. The company’s focus on miroliverELAP™ and the initiation of a Phase 1 clinical trial for this technology is a major milestone that will provide validation for its bioengineering technology platform.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Niowave to expand in Michigan, driving $20M investment and creating 35 high-paying jobs in life sciences and tech industry

Niowave Inc, a global producer of medical isotopes, has announced plans to expand in Lansing, Michigan, which will drive $20 million in investment and create 35 good-paying jobs in the life sciences and tech industry. The project is supported by a $500,000 Jobs Ready Michigan Program performance-based grant. Niowave is one of the few companies worldwide that can design, build, test and operate superconducting linear accelerators in their own facility.

Niowave was established in 2005 as a spinoff from the National Superconducting Cyclotron Lab, the laboratory now known as Facility for Rare Isotope Beams (FRIB), which the MEDC supported in February 2014 and officially opened in May 2022. Niowave supplies medical and industrial radioisotopes produced from uranium and radium.

The company chose Michigan for the project over competing sites in California, Indiana, South Carolina, and Tennessee to take advantage of the regional talent pool that combines the advanced manufacturing heritage and the number one-rated nuclear physics program at Michigan State University. The company plans to grow at its existing facility in Lansing near the Capital Region International Airport, where it will expand production of several medical radioisotopes used in diagnostic and therapeutic treatments. These isotopes enable the detection of life-threatening conditions such as cancer and heart disease for better patient outcomes.

Niowave currently ships cancer treatments from its Lansing facilities, and the expansion will allow for higher production of these important medical radioisotopes. The project will bring immediate, high-wage jobs in the tech and life sciences industries to the region and has the potential to make mid-Michigan an “isotope capital,” building on the work currently being done at the FRIB at Michigan State University.

Niowave’s expansion in Lansing is a testament to Michigan’s leadership in high tech and life sciences, as well as the strength of its business climate and talented workforce. MEDC Sr. Vice President of Regional Prosperity Matt McCauley stated that the project is a win for Lansing and for the entire state. Local officials, the Lansing Economic Area Partnership, and the Next Michigan Development Corporation are working to support the project, and Niowave intends, pending key local, state, and federal approvals that make the expansion possible, to proceed with the project later this year.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Ucore Invests $75 Million to Establish Rare Earth Metals Manufacturing Facility in Alexandria

Ucore North America, a subsidiary of Ucore Rare Metals Inc., has recently announced its investment of $75 million to build North America’s first modern technology rare earth element separation and purification facility in Rapides Parish. The facility, called the Louisiana Strategic Metals Complex, is set to create a U.S.-based supply chain of rare earth oxides that are required to manufacture electric vehicle motors, wind turbine generators, smart phones, and power tools.

The establishment of this facility represents an important step towards establishing the critical metals supply chain necessary for the changing manufacturing landscape across North America. By producing materials for industrial rare earth permanent magnets used in electric vehicles and wind turbines, Ucore is contributing to the shift towards energy production and consumption diversification.

The Louisiana facility will create 100 new direct jobs with an average annual salary of more than $50,000. Louisiana Economic Development estimates the project will result in 298 additional new indirect jobs, for a total of 398 new jobs in the Central Region.

The facility will provide the space and means necessary to implement Ucore’s proprietary critical metals separation technology, converting thousands of metric tons of high-purity earth feedstocks into usable materials.

The establishment of the Louisiana Strategic Metals Complex is a major manufacturing project that illustrates how the shift towards cleaner energy is creating jobs and increasing investment across the state. The products manufactured at Ucore will reinforce Louisiana’s importance to the global supply chain, and the company’s decision to locate its Strategic Metals Complex in Alexandria is an important strategic and economic development victory for Louisiana and the region.

The investment is part of Ucore’s vision and plan to become a leading advanced technology company, providing best-in-class metal separation products and services to the nascent North American rare earth element supply chain. This plan includes the near-term development of a heavy and light rare-earth processing facility in Louisiana, with subsequent facilities in Canada, Alaska, and the longer-term development of Ucore’s heavy-rare-earth-element mineral-resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Sivananthan Labs: Leading the Way in Quantum Sensing

Sivananthan Laboratories Inc. has announced the successful completion of a $1.5M award from the Small Business Technology Transfer (STTR) Phase II program for the development of an entangled short-wavelength infrared (En-SWIR) photon source. This is an exciting development in the field of quantum sensing and promises many orders of magnitude enhancements in imaging, sensing, computing, metrology, and communication.

The En-SWIR entangled photon source and detector system envisioned by Sivananthan Laboratories, featuring advanced image processing algorithms, ultimately promises to be an enabling technology for rapid and effective decision making, increasing the speed and reach of disruption of any defense forces. This development is consistent with Sivananthan Laboratories’ business model and long-standing commitment to developing advanced technology for the US military.

Led by Dr. Paul Boieriu, the latest development follows the initial success of their Phase I project which established proof of concept and demonstrated remarkable potential of the fast-emerging field of quantum sensing. The project operates on the concept that when used as part of Sivananthan Laboratories’ imaging system, the En-SWIR increases signal-to-noise ratio, allowing for non-direct-line-of-sight imaging of distant objects with increased image quality and low power consumption, making it ideally suitable for space-based applications.

Sivananthan Laboratories is a high-tech business incubator and a national leader in the infrared sensing and imaging industry. The company was formed in September 2009 with a mission to nurture and foster the development of cutting-edge research in areas pertaining to national security, both physical and economic, and socio-economic development.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Cradlepoint’s Acquisition of Ericom Software: A Boost to Enterprise Security in 5G Settings

Cradlepoint, a wireless WAN vendor based in Boise, Idaho, has made a bold move in the security sector. The company recently acquired Ericom Software, an Israeli cybersecurity veteran, to expand its SASE, zero trust, and cloud security offerings. The purchase of Ericom will bolster Cradlepoint’s mobile-capable and router-integrated SASE and zero trust technology portfolio, which can now cover fixed-site, remote worker, in-vehicle, and IoT use cases. The acquisition is a key part of Cradlepoint’s strategy to build a full-stack enterprise security service optimized for 5G.

Founded in 1993, Ericom Software has experienced three decades of bootstrapped growth, employing 111 people without taking any outside funding. Ericom CEO David Canellos is excited about the acquisition, as it enhances the company’s ability to meet the cybersecurity needs of global enterprises as they accelerate their rapid adoption of 5G technologies.

Cradlepoint’s SD-WAN and security strategy is based on the belief that enterprises will not deploy products from multiple vendors to address wireless and wireline network infrastructures. Therefore, the company’s SASE and zero trust offering will interoperate with its SD-WAN platform. Cradlepoint has more than 10,000 SD-WAN customers, and its market operations are focused on North America.

While Ericom historically focused on remote access and web security, it has recently debuted a full SASE platform in 2022 that includes SD-WAN, firewall, network access, data loss prevention, and basic access management with multi factor authentication.

Cradlepoint’s acquisition of Ericom is the second since March focused on delivering single-vendor SASE, and it comes a month after Hewlett Packard Enterprise bought security service edge startup Axis Security. As cybersecurity becomes increasingly critical in the 5G era, more companies are likely to follow suit and acquire established security vendors to expand their portfolios.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.